The effect of SSRI/SNRI antidepressant treatment on the gut microbiota of patients with major depressive disorder.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Natasha Eugenia Emile, Mulder Danique, Fehse Leon, Winter Nils R, Fisch Lukas, Welzel Marius, Bang Corinna, Meinert Susanne, Flinkenflügel Kira, Borgers Tiana, Goltermann Janik, Leehr Elisabeth J, Culmsee Carsten, Stein Frederike, Thomas-Odenthal Florian, Usemann Paula, Teutenberg Lea, Nenadic Igor, Straube Benjamin, Alexander Nina, Jamalabadi Hamidreza, Jansen Andreas, Nitsch Robert, Lügering Andreas, Franke Andre, Dannlowski Udo, Kircher Tilo, Heider Dominik, Hahn Tim, Vrijsen Janna N, van Eijndhoven Philip, Tendolkar Indira, Reif Andreas, Edwin Thanarajah Sharmili, Matura Silke, Arias Vasquez Alejandro, Bloemendaal Mirjam
Аннотация
METHODS: We conducted cross-sectional analyses in two independent patient cohorts (total N = 1802) and a meta-analysis across both cohorts, comparing the gut microbiome of MDD patients with and without SSRI/SNRI treatment.
RESULTS: Here we show that SSRI/SNRI treatment is consistently associated with reduced Clostridium sensu stricto 1 abundance. This effect is specific to SSRI/SNRI treatment and not observed with other psychotropic medications. Importantly, reductions in Clostridium sensu stricto 1 in MDD compared to unaffected controls are explained by SSRI/SNRI medication status.
CONCLUSIONS: Antidepressant treatment is an important factor shaping gut microbiome alterations linked to MDD, underscoring the need to account for medication effects and potentially informing future microbiome-based strategies to improve treatment response.